ArticleFrontiers in genetics2026
Exploring the potential targets and possible mechanisms of Shenqi Fuzheng Injection in the treatment of cancer-associated muscle wasting based on network pharmacology.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer-associated muscle wasting (CAMW) is a debilitating condition observed in cancer patients, characterized by progressive skeletal muscle loss driven by tumor-secreted inflammatory cytokines, metabolic reprogramming, and enhanced apoptotic signaling, severely affecting the quality of life of patients. Shenqi Fuzheng Injection (SFI) is a traditional Chinese medicine preparation made from Codonopsis pilosula (Dangshen) and Astragalus membranaceus (Huangqi) in specific proportions, which has the effects of replenishing qi, strengthening the body, alleviating the side effects of radiotherapy and chemotherapy, relieving fatigue, and enhancing immune function. This study aims to explore the potential mechanisms of SFI in cancer-associated muscle wasting-a clinically significant form of sarcopenia frequently observed in cancer patients-through network pharmacology and molecular docking techniques. The key components in Shenqi Fuzheng Injection were found to have strong binding affinity with Caspase-3, Caspase-8, TNF, and TP53. Cell experiments further verified the effects of Shenqi Fuzheng Injection in alleviating mitochondrial damage in myoblasts and reducing apoptosis. Comprehensive analysis indicates that Shenqi Fuzheng Injection may target Caspase-3 and Caspase-8 to reduce apoptosis, thereby achieving therapeutic effects on cancer-associated muscle wasting. This study is exploratory and hypothesis-generating in nature; further
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.